Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Effect of Inhaled Cannabis for Pain in Adults With Sickle Cell Disease: A Randomized Clinical Trial
source: JAMA Network Open
authors: Donald I. Abrams, Paul Couey, Niharika Dixit, Varun Sagi, Ward Hagar, Elliott Vichinsky, Mary Ellen Kelly, John E. Connett, Kalpna Guptasummary/abstract:
To determine whether inhaled cannabis is more effective than inhaled placebo in relieving chronic pain in adults with SCD.
Design, Setting, and Participants:
This pilot randomized clinical trial included participants with SCD with chronic pain admitted to a single inpatient clinical research center for 2 separate 5-day stays from August 2014 to April 2017. Participants inhaled either vaporized cannabis (4.4% Δ-9-tetrahydrocannabinol to 4.9% cannabidiol) 3 times daily or vaporized placebo cannabis. Pain and pain interference ratings using the Brief Pain Inventory were assessed throughout each 5-day period. Participants with SCD and chronic pain on stable analgesics were eligible to enroll. A total of 90 participants were assessed for eligibility; 56 participants were deemed ineligible, and 34 participants were enrolled. Of these, 7 participants dropped out before randomization. Of 27 randomized participants, 23 completed both treatment arms of the crossover study and were included in the final per protocol analysis. Data analysis was completed in June 2019, with the sensitivity analysis conducted in April 2020.
Inhalation of vaporized cannabis plant (4.4% Δ-9-tetrahydrocannbinol to 4.9% cannabidiol) or placebo cannabis plant using a vaporizer 3 times daily for 5 days.
Main Outcomes and Measures:
Daily pain assessed with visual analog scale and Brief Pain Inventory.
A total of 23 participants (mean [SD] age, 37.6 [11.4] years; 13 [56%] women) completed the trial. The mean (SD) difference in pain rating assessment between the cannabis and placebo groups was -5.3 (8.1) for day 1, -10.9 (7.0) for day 2, -16.5 (9.2) for day 3, -8.9 (6.7) for day 4, and -8.2 (8.1) for day 5; however, none of these differences were statistically significant. There was no statistically significant mean (SD) difference in pain interference ratings between cannabis and placebo between days 1 and 5 for interference in general activities (day 1: 0.27 [0.35]; day 5: -1.0 [0.5]), walking (day 1: 0.14 [0.73]; day 5: -0.87 [0.63]), sleep (day 1: 0.59 [0.74]; day 5: -1.3 [0.8]), or enjoyment (day 1: 0.23 [0.69]; day 5: -0.91 [0.48]), but there was a statistically significant mean (SD) difference in decrease in interference with mood (day 1: 0.96 [0.59]; day 5: -1.4 [0.6]; P = .02). No differences in treatment-related adverse effects were observed. Use of concomitant opioids was similar during both treatment periods.
Crizanlizumab designated FDA breakthrough therapy for potential in vaso-occlusive crisis preventionCrizanlizumab (SEG101), Novartis‘ inve...
Virtual Reality Helps Reduce Pain Among Patients With Sickle Cell DiseaseImmersive virtual reality appeared effec...
Data Brief: Healthcare Utilization for Vaso-Occlusive Episodes by People with Sickle Cell Disease in California and ...Many people with sickle cell disease (SC...
Acute Care Utilization Is More Common in Patients with Sickle Cell Disease Who Have Chronic Complications and Chroni...Background: We undertook a large multisi...
Researchers raise funds for phase 1 trial to test medical cannabis in sickle cell diseaseThe Sickle Cell Foundation of Georgia ...
Safety and early hints of benefit seen in phase 1b trial of PF-04447943Sickle cell disease (SCD) patients were ...
Living With Unpredictable Pain: A Sickle Cell Disease StoryGrowing up, Vismel Marquez wanted to joi...
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.